CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

被引：19

作者：

Agha, Mounzer E.

Cohen, Adam D.

Madduri, Deepu

Cohen, Yael C.

Delforge, Michel

Hillengass, Jens

Goldschmidt, Hartmut

Weisel, Katja

Raab, Marc-Steffen

Scheid, Christof

Schecter, Jordan Mark

De Braganca, Kevin C.

Varsos, Helen

Wang, Liwei

Vogel, Martin

Carrasco-Alfonso, Marlene

Akram, Muhammad

Wu, Xiaoling

Nesheiwat, Tonia

Einsele, Hermann

机构：

[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Mt Sinai Med Ctr, New York, NY 10029 USA

[4] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[5] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[6] Univ Ziekenhuizen Leuven, Leuven, Belgium

[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[8] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[9] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[10] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[11] Univ Hosp Heidelberg, Heidelberg, Germany

[12] Univ Cologne, Cologne, Germany

[13] Janssen R&D, Raritan, NJ USA

[14] Janssen Global Serv LLC, Raritan, NJ USA

[15] Legend Biotech USA Inc, Piscataway, NJ USA

[16] Legend Biotech USA Inc, Somerset, NJ USA

[17] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.8013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8013

引用

页数：3